U.S. flag

An official website of the United States government

NM_000116.5(TAFAZZIN):c.270G>A (p.Leu90=) AND 3-Methylglutaconic aciduria type 2

Germline classification:
Likely benign (2 submissions)
Last evaluated:
Jan 7, 2024
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001168188.6

Allele description

NM_000116.5(TAFAZZIN):c.270G>A (p.Leu90=)

Gene:
TAFAZZIN:tafazzin, phospholipid-lysophospholipid transacylase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
Xq28
Genomic location:
Preferred name:
NM_000116.5(TAFAZZIN):c.270G>A (p.Leu90=)
HGVS:
  • NC_000023.11:g.154413238G>A
  • NG_009634.2:g.6704G>A
  • NG_012884.2:g.3851C>T
  • NM_000116.5:c.270G>AMANE SELECT
  • NM_001303465.2:c.324G>A
  • NM_181311.4:c.270G>A
  • NM_181312.4:c.270G>A
  • NM_181313.4:c.270G>A
  • NP_000107.1:p.Leu90=
  • NP_001290394.1:p.Leu108=
  • NP_851828.1:p.Leu90=
  • NP_851829.1:p.Leu90=
  • NP_851830.1:p.Leu90=
  • LRG_131t1:c.270G>A
  • LRG_131:g.6704G>A
  • LRG_131p1:p.Leu90=
  • NC_000023.10:g.153641575G>A
  • NC_000023.10:g.153641575G>A
  • NG_009634.1:g.6699G>A
  • NM_000116.3:c.270G>A
  • NR_024048.3:n.575G>A
Links:
dbSNP: rs781986219
NCBI 1000 Genomes Browser:
rs781986219
Molecular consequence:
  • NR_024048.3:n.575G>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NM_000116.5:c.270G>A - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001303465.2:c.324G>A - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_181311.4:c.270G>A - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_181312.4:c.270G>A - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_181313.4:c.270G>A - synonymous variant - [Sequence Ontology: SO:0001819]

Condition(s)

Name:
3-Methylglutaconic aciduria type 2 (BTHS)
Synonyms:
Barth syndrome; 3-methylglutaconicaciduria type II; MGA type II; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0010543; MedGen: C0574083; Orphanet: 111; OMIM: 302060

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001330764Illumina Laboratory Services, Illumina
criteria provided, single submitter

(ICSL Variant Classification Criteria 13 December 2019)
Likely benign
(Jan 13, 2018)
germlineclinical testing

Citation Link,

SCV003282162Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Likely benign
(Jan 7, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Illumina Laboratory Services, Illumina, SCV001330764.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
2not providednot providednot providednot providedclinical testingnot provided

Description

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided
2germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Invitae, SCV003282162.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Apr 6, 2024